Design, Syntheses, and SAR Studies of Carbocydic Analogues of Sergliflozin as Potent Sodium-Dependent Glucose Cotransporter 2 Inhibitors

摘要

Type 2 diabetes mellitus (T2DM) or noninsulin-dependent DM, is the most common type of diabetes. The number of patients suffering from T2DM worldwide is expected to rise to 380 million by 2025. Unfortunately, current therapeutic agents are not effective enough such that only less than 36 % of the patients have been treated satisfactorily; in addition many side effects are associated with the medicine. Thus, we set out to develop novel small-molecule carbohydrate mimics as potential antidiabetic agents to supplement the existing medication. Our endeavors in the synthesis of carbohydrate mimics have already produced potent α-glucosidase inhibitors as potential antidiabetic molecules. We herein report the design, syntheses, and structure-activity relationship (SAR) studies of another class of potential antidiabetic agents—transporter protein inhibitors.